WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

Model scores of the 29,894 trials active now.

Model score 22% for any early termination, 8% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2018-10-17. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: patientstemhearttransplantationqt
  Phrases that lowered it: elderlyamlaminotransferaseleukemiacytarabine
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 13.2% (raises risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Drug's FAERS reports with a death: 29.3% (raises risk) · Drug's FDA history
• Disease area, cancer: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 213 (lowers risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Drug's FAERS reports marked serious: 96.6% (raises risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Sponsor's past trials: 729 (lowers risk) · Sponsor's track record
• Collaborators: 1 (raises risk) · Design
• Responsible party: sponsor (lowers risk) · Design
• Blinding: none (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis NCT03718143 · started 2019 · scored riskier than 96% of active trials terminated
• Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies. NCT03218683 · started 2017 · scored riskier than 59% of active trials terminated
• Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia NCT02381548 · started 2015 · scored riskier than 88% of active trials terminated
• Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors NCT02095132 · started 2014 · scored riskier than 76% of active trials completed
• MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia NCT01231919 · started 2011 · scored riskier than 22% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.